Sibeprenlimab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Journal: BMC nephrology
Published: January 27, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: December 22, 2025
Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Journal: Cureus
Published: December 21, 2025
Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents.
Journal: BMC nephrology
Published: December 19, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Journal: The New England journal of medicine
Published: November 10, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.
Journal: Kidney international reports
Published: June 06, 2025
Safety Reporting for Auxiliary Medicinal Products in the Sibeprenlimab Phase-III Study According to the New European Union (536/2014) CT Regulation.
Journal: Current drug safety
Published: November 08, 2024
Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.
Journal: Frontiers in medicine
Published: October 30, 2024
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy.
Journal: Expert opinion on biological therapy
Published: April 20, 2024
Last Updated: 06/30/2026